{"gene":"PHOSPHO1","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2004,"finding":"Human PHOSPHO1 exhibits high specific phosphatase activities toward phosphoethanolamine (PEA) and phosphocholine (PCho), generating inorganic phosphate (Pi). Optimal activity is at pH ~6.7, requires Mg2+, with Km values of 3.0 µM for PEA and 11.4 µM for PCho.","method":"In vitro enzymatic assay with recombinant human PHOSPHO1","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro enzymatic characterization with kinetic parameters, replicated in subsequent studies","pmids":["15175005"],"is_preprint":false},{"year":2003,"finding":"Comparative modelling of human PHOSPHO1 based on phosphoserine phosphatase crystal structure revealed a catalytic Mg2+ coordinated by conserved Asp32, Asp34, and Asp203; Asp43 and Asp123 (not present in PSPs) contribute to substrate specificity, placing PHOSPHO1 in a novel subgroup of the HAD superfamily distinct from phosphoserine phosphatases.","method":"Homology modelling based on crystal structure of phosphoserine phosphatase from Methanococcus jannaschii","journal":"Protein engineering","confidence":"Medium","confidence_rationale":"Tier 1 (structural model) / Weak — single-lab computational model without experimental structural validation; functional predictions later partially confirmed by mutagenesis","pmids":["14983068"],"is_preprint":false},{"year":2005,"finding":"Active-site mutagenesis of PHOSPHO1 confirmed that Asp32 and Asp203 are essential catalytic residues; mutation of either abolishes activity, confirming membership in the HAD superfamily. Asp43 and Asp123 are also important for substrate hydrolysis. By contrast, PHOSPHO2 (42% identity) shows high activity toward pyridoxal-5-phosphate rather than PEA/PCho, indicating distinct substrate specificities despite similar active-site architecture.","method":"Site-directed mutagenesis of recombinant PHOSPHO1 and PHOSPHO2, in vitro enzymatic assay","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — active-site mutagenesis combined with kinetic characterization of both paralogs in a single study","pmids":["16054448"],"is_preprint":false},{"year":2004,"finding":"PHOSPHO1 protein localizes exclusively to mineralizing regions: osteoid of periosteum, forming surfaces of growing osteons, newly formed osteocytes, early hypertrophic chondrocytes of growth plate, and primary spongiosa; absent from soft tissues. PHOSPHO1 gene expression is detected in mineralizing SaOS-2 but not non-mineralizing MG-63 osteoblast-like cells.","method":"Immunohistochemistry of avian skeletal tissues with affinity-purified antiserum; RT-PCR in osteoblast cell lines","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by IHC with functional correlation (mineralizing vs. non-mineralizing cells), replicated across subsequent studies","pmids":["15050893"],"is_preprint":false},{"year":2006,"finding":"PHOSPHO1 is present within matrix vesicles (MVs) isolated from growth plate chondrocytes, as confirmed by immunoblotting. PHOSPHO1 expression in MVs is upregulated alongside TNAP activity when chondrocytes are induced to differentiate with ascorbic acid. PHOSPHO1 mRNA expression during chick embryogenesis precedes mineral deposition, appearing first in the bone collar of the diaphysis.","method":"Immunoblotting of isolated MVs; whole-mount in situ hybridization; qPCR; alizarin red/alcian blue staining","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct MV localization by Western blot replicated by multiple subsequent studies; developmental expression precedes mineralization confirmed independently","pmids":["16837257"],"is_preprint":false},{"year":2007,"finding":"PHOSPHO1 is functionally present within MVs in an active state (PEA hydrolase activity detected in sonicated but not intact MVs from TNAP-deficient osteoblasts). Pharmacological inhibition of PHOSPHO1 with lansoprazole or SCH202676 reduced MV-mediated mineralization by 56.8% and 70.7%, respectively, establishing a functional role in the initiation of MV-mediated calcification.","method":"High-throughput screening of chemical libraries; enzymatic assay on sonicated/intact MVs from Akp2-/- osteoblasts; mineralization assay with isolated MVs","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — enzymatic activity in isolated MVs combined with pharmacological inhibition and mineralization readout; replicated across labs","pmids":["17227223"],"is_preprint":false},{"year":2010,"finding":"Genetic ablation of PHOSPHO1 (Phospho1-/- mice) causes growth plate abnormalities, spontaneous fractures, bowed long bones, osteomalacia, and scoliosis. Primary Phospho1-/- chondrocytes and their MVs show reduced mineralizing ability. Plasma PP(i) is elevated in Phospho1-/- mice. Transgenic overexpression of TNAP in Phospho1-/- mice normalizes PP(i) but does NOT correct the bone phenotype, demonstrating PHOSPHO1 has a non-redundant role independent of PP(i) control. Double ablation of PHOSPHO1 and TNAP completely abolishes skeletal mineralization and causes perinatal lethality, establishing their cooperative, non-redundant roles.","method":"Knockout mouse generation; histology; primary chondrocyte culture; MV isolation and mineralization assay; biochemical plasma analysis; genetic double-knockout epistasis","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with multiple knockout models, multiple orthogonal phenotypic readouts, replicated across labs","pmids":["20684022"],"is_preprint":false},{"year":2010,"finding":"PHOSPHO1 deficiency in MVs secondarily reduces TNAP levels in Phospho1-/- MVs, affecting ATP hydrolysis in those MVs. TNAP is the primary enzyme hydrolyzing both ATP and PP(i) within the MV compartment; lack of NPP1 does not significantly affect MV kinetic parameters for any substrate.","method":"Kinetic analysis of phosphosubstrate hydrolysis by isolated MVs from WT, TNAP-/-, NPP1-/-, and PHOSPHO1-/- osteoblasts at physiologic pH","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct kinetic comparison across four genetically defined MV preparations, rigorous biochemical assay","pmids":["19874193"],"is_preprint":false},{"year":2010,"finding":"Pharmacological inhibition of PHOSPHO1 (lansoprazole) in developing chick limb micromass cultures and in ovo completely inhibited mineralization of long bones. PHOSPHO1 and TNAP are co-expressed in a tightly regulated pattern preceding mineralization. The talpid3 chick mutant (defective hedgehog signaling, no endochondral mineralization) lacks Phospho1 and Tnap expression, while flat bones that mineralize normally express both, linking hedgehog signaling to PHOSPHO1-dependent endochondral ossification.","method":"In vitro micromass cultures with lansoprazole inhibitor; whole-mount RNA in situ hybridization; talpid3 mutant analysis; alizarin red/alcian blue staining","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition in two experimental systems plus genetic mutant comparison, single lab","pmids":["20053388"],"is_preprint":false},{"year":2013,"finding":"PHOSPHO1 is expressed in vascular smooth muscle cells (VSMCs) under calcifying conditions, and Phospho1-/- VSMCs fail to mineralize in vitro. Pharmacological inhibition of PHOSPHO1 with MLS-0263839 reduced VSMC calcification to 41.8% of control; combined PHOSPHO1 + TNAP inhibition reduced it to 20.9% of control, demonstrating PHOSPHO1 plays a critical role in VSMC (vascular) mineralization.","method":"Knockout VSMC cultures; pharmacological inhibitors; mineralization assay; gene expression analysis","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout combined with pharmacological inhibition and quantitative mineralization readout, multiple orthogonal approaches","pmids":["22887744"],"is_preprint":false},{"year":2014,"finding":"Phospho1-/- mice have elevated plasma osteopontin (OPN) and increased proportion of phosphorylated OPN (p-OPN) in the skeleton detected by LC-MS/MS. Ablation of Spp1 (OPN gene) in Phospho1-/- mice rescues scoliosis and improves long bone defects and normalizes chondrocyte differentiation markers, establishing that accumulated phosphorylated OPN mediates the skeletal abnormalities in Phospho1-/- mice (distinct from the PP(i)-mediated mechanism in TNAP-deficient mice).","method":"Double-knockout mouse generation; LC-MS/MS for p-OPN quantification; histology; mineralization assay; gene expression analysis","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (double KO) with LC-MS/MS biochemical validation and multiple phenotypic readouts","pmids":["24825455"],"is_preprint":false},{"year":2016,"finding":"Combined genetic ablation of Phospho1 and the phosphate transporter Pit1 (Slc20a1, col2a1-Cre) produces more severe skeletal deformities than Phospho1-/- alone. ~80% of [Phospho1-/-; Pit1col2/col2] MVs are devoid of mineral vs. ~50% for Phospho1-/- and ~25% for WT, assessed by atomic force microscopy. PHOSPHO1 function is also involved in MV biogenesis, as both Phospho1-/- and double-KO chondrocytes produce significantly fewer MVs.","method":"Conditional double-knockout mouse model; atomic force microscopy of MVs; histology; micro-CT; biomechanical testing","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double conditional KO, quantitative AFM of MV mineral content, multiple orthogonal structural and functional readouts","pmids":["26773408"],"is_preprint":false},{"year":2016,"finding":"PTH continuously downregulates Phospho1 and Smpd3 (nSMase2) gene expression in osteoblast cultures and hemi-calvariae. This effect is mimicked by the cAMP agonist forskolin and blocked by the PKA inhibitor PKI(5-24), identifying the cAMP/PKA pathway as the mediator of PTH-driven PHOSPHO1 suppression. BMP-2's stimulatory effect on Phospho1 expression is abolished by PTH.","method":"In vitro osteoblast cultures (MC3T3-C14); hemi-calvaria cultures; pharmacological agonist/inhibitor studies; gene expression analysis (qPCR)","journal":"Calcified tissue international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway placement via pharmacological epistasis (cAMP agonist + PKA inhibitor), two model systems, single lab","pmids":["27444010"],"is_preprint":false},{"year":2016,"finding":"PHOSPHO1 (expressed by cementoblasts and alveolar bone osteoblasts) is required for cellular cementum and alveolar bone mineralization. Phospho1-/- mice show increased cementoid (delayed mineralization) in cellular cementum and unmineralized osteoid in alveolar bone with elevated OPN deposition, while acellular cementum is unaffected, demonstrating acellular cementum does not rely on MV-mediated (PHOSPHO1-dependent) initiation of mineralization.","method":"Phospho1-/- mouse analysis; histology; immunohistochemistry; in situ hybridization; micro-CT; radiography","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout mouse with tissue-specific phenotypic readouts and spatial protein localization, single lab","pmids":["27016531"],"is_preprint":false},{"year":2015,"finding":"PHOSPHO1 and TNAP have non-redundant, cooperative roles in osteoblast mineralization. In MC3T3-E1 clone 24 cells (low PHOSPHO1/high TNAP), lentiviral PHOSPHO1 overexpression increases both PHOSPHO1 and TNAP protein and enhances mineralization. Simultaneous pharmacological inhibition of both PHOSPHO1 and TNAP essentially abolishes mineralization (85% reduction), whereas individual inhibitors only partially suppress it.","method":"Lentiviral overexpression; pharmacological inhibitors (MLS-0263839 and MLS-0038949); mineralization assays in MC3T3-E1 cell clones and ex vivo metatarsal cultures","journal":"Biochemistry and biophysics reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal gain/loss-of-function approaches in multiple model systems, single lab","pmids":["26457330"],"is_preprint":false},{"year":2008,"finding":"A novel alternatively spliced PHOSPHO1 transcript (PHOSPHO1-3a) was identified, encoding a 292-amino-acid protein with a 40-amino-acid N-terminal region containing a predicted secretory signal while retaining all three HAD superfamily catalytic domains. Expression confirmed in human and mouse osteoblast-like cells and chondrogenic ATDC5 cells.","method":"RT-PCR; sequence analysis; expression in osteoblast and chondrogenic cell lines","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — transcript identification confirmed by RT-PCR in multiple cell lines but no functional characterization of the protein isoform","pmids":["18471996"],"is_preprint":false},{"year":2017,"finding":"PHOSPHO1 localizes to ameloblast Tomes' processes and secretory vesicle walls (co-localizing with amelogenin and the exosomal marker HSP70). Phospho1-/- mice display reduced enamel mineralization (2-fold reduction in von Kossa silver grain density), loss of enamel prism 'picket fence' structure, loss of parallel crystal organization, increased prism width, and decreased phosphate incorporation by EDS, establishing PHOSPHO1 as essential for enamel mineralization.","method":"Immunohistochemistry; Western blot; scanning electron microscopy; EDS elemental analysis; von Kossa staining; Phospho1-/- mouse model","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout mouse with multiple structural and quantitative mineral readouts, single lab","pmids":["29089903"],"is_preprint":false},{"year":2020,"finding":"PHOSPHO1 knockout mice are cold-tolerant and protected from high-fat diet-induced obesity and insulin resistance. PHOSPHO1 substrate phosphocholine (PC) accumulation (via exogenous PC treatment) is sufficient to induce thermogenic gene expression in BAT and cold tolerance, establishing PHOSPHO1 as a negative regulator of BAT thermogenesis through its phosphocholine phosphatase activity.","method":"Phospho1-/- mouse model; cold tolerance testing; high-fat diet challenge; thermogenic gene expression analysis; exogenous phosphocholine treatment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO combined with substrate rescue experiment, two orthogonal approaches, single lab","pmids":["32554489"],"is_preprint":false},{"year":2020,"finding":"Phospho1-/- mice exhibit improved basal glucose homeostasis and resist high-fat diet-induced weight gain and diabetes independently of osteocalcin levels. Decreased serum choline in Phospho1-/- mice is normalized by 2% choline diet feeding, which also normalizes insulin sensitivity and fat mass, establishing that PHOSPHO1's metabolic regulation is mediated via choline availability.","method":"Phospho1-/- mouse model; HFD challenge; dietary choline supplementation rescue; serum metabolite measurement; gene expression analysis in osteoblasts","journal":"BMC biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with dietary rescue experiment establishing the choline-mediated mechanism, single lab","pmids":["33092598"],"is_preprint":false},{"year":2021,"finding":"All tested proton pump inhibitors (PPIs) inhibit PHOSPHO1 enzymatic activity in vitro (IC50 range: 0.73 µM for esomeprazole to 19.27 µM for pantoprazole), whereas histamine-2 receptor antagonists do not. Several PPIs inhibit mineralization of bone matrix in primary osteoblast cultures in a concentration-dependent manner, providing a potential mechanism for PPI-associated fracture risk.","method":"In vitro PHOSPHO1 enzymatic inhibition assay; primary osteoblast mineralization cultures","journal":"Calcified tissue international","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — direct enzymatic IC50 determination combined with cell-based mineralization assay, single lab","pmids":["34213594"],"is_preprint":false},{"year":2022,"finding":"In a CKD (renal osteodystrophy) mouse model, cortical bone mineral density is increased alongside upregulated PHOSPHO1 expression. In Phospho1-/- CKD mice, the cortical BMD increase is rescued, establishing that elevated PHOSPHO1 expression directly drives the cortical BMD phenotype in CKD. PTH and phosphate treatment of primary osteoblasts downregulate both PHOSPHO1 and TNAP expression.","method":"Dietary adenine CKD model in WT and Phospho1-/- mice; micro-CT; primary osteoblast cultures with PTH/phosphate treatment; gene expression analysis","journal":"The Journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue in KO CKD model with quantitative BMD readout and in vitro mechanistic follow-up, single lab","pmids":["35900032"],"is_preprint":false},{"year":2025,"finding":"PHOSPHO1 (cytosolic protein) exhibits D609-sensitive phosphatidylcholine-PLC (PC-PLC) and phosphatidylethanolamine-PLC (PE-PLC) activities in vitro, generating diacylglycerol (DG). Overexpression of PHOSPHO1 in HEK293 cells significantly increases cellular levels of saturated/monounsaturated fatty acid-containing DG. PHOSPHO1 co-sediments and co-localizes with diacylglycerol kinase δ (DGKδ), identifying it as a candidate cytosolic PC-/PE-PLC acting upstream of DGKδ.","method":"In vitro PLC activity assay; PHOSPHO1 overexpression in HEK293 cells; lipidomic analysis; co-sedimentation; co-localization","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 1-2 / Weak — novel activity demonstrated in vitro with cellular overexpression and co-sedimentation, but single lab, first report of this activity","pmids":["39992810"],"is_preprint":false},{"year":2024,"finding":"Lansoprazole (LPZ) inhibits adipose PHOSPHO1 (phosphocholine phosphatase) activity and produces metabolic benefits (reduced obesity, insulin resistance, hepatic steatosis, induction of thermogenic gene expression) in a PHOSPHO1-dependent manner in mice. Mechanistically, LPZ may stimulate thermogenesis by inhibiting conversion of 2-AG-LPA to 2-AG, reducing cannabinoid receptor signaling.","method":"In vitro PHOSPHO1 inhibition assay; HFD mouse model with LPZ treatment; PHOSPHO1-dependent rescue experiments; gene expression analysis; mitochondrial respiration assay","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition validated in PHOSPHO1-dependent manner with in vitro and in vivo readouts, single lab","pmids":["38572109"],"is_preprint":false}],"current_model":"PHOSPHO1 is a Mg2+-dependent phosphatase of the HAD superfamily (catalytic residues Asp32, Asp203, Asp43, Asp123) that hydrolyzes phosphoethanolamine and phosphocholine to generate inorganic phosphate within matrix vesicles, initiating hydroxyapatite crystal nucleation during endochondral ossification; it also exhibits PC-PLC and PE-PLC activities generating diacylglycerol and acts as a negative regulator of brown adipose tissue thermogenesis through phosphocholine hydrolysis, with its catabolic effects on choline availability mediating systemic metabolic regulation, while its expression is controlled by the cAMP/PKA pathway downstream of PTH signaling."},"narrative":{"mechanistic_narrative":"PHOSPHO1 is a Mg2+-dependent phosphatase of the HAD superfamily that initiates skeletal mineralization by hydrolyzing phosphoethanolamine and phosphocholine within matrix vesicles to generate the inorganic phosphate required for hydroxyapatite crystal nucleation [PMID:15175005, PMID:16837257, PMID:17227223]. Catalysis depends on the conserved active-site aspartates Asp32 and Asp203, with Asp43 and Asp123 conferring substrate specificity that distinguishes it from phosphoserine phosphatases and from the paralog PHOSPHO2 [PMID:14983068, PMID:16054448]. The protein is restricted to mineralizing tissues and packaged into matrix vesicles of growth plate chondrocytes and osteoblasts, where its expression precedes mineral deposition [PMID:15050893, PMID:16837257]. Genetic ablation produces growth plate abnormalities, spontaneous fractures, bowed long bones, and osteomalacia, and PHOSPHO1 cooperates non-redundantly with the alkaline phosphatase TNAP: double ablation abolishes skeletal mineralization and causes perinatal lethality, while TNAP overexpression cannot rescue the Phospho1-/- bone defect despite normalizing pyrophosphate [PMID:20684022, PMID:26457330]. The Phospho1-/- skeletal phenotype is instead mediated by accumulation of phosphorylated osteopontin, since co-deletion of Spp1 rescues the abnormalities [PMID:24825455]. PHOSPHO1-dependent matrix-vesicle mineralization also drives cementum, alveolar bone, enamel, and pathological vascular smooth muscle cell calcification [PMID:22887744, PMID:27016531, PMID:29089903]. Beyond mineralization, PHOSPHO1 acts as a negative regulator of brown adipose tissue thermogenesis and systemic glucose homeostasis through its phosphocholine phosphatase activity, with effects mediated by choline availability [PMID:32554489, PMID:33092598]. It additionally exhibits PC-PLC and PE-PLC activity generating diacylglycerol and co-localizes with diacylglycerol kinase δ [PMID:39992810]. Its expression is suppressed by PTH via the cAMP/PKA pathway [PMID:27444010], and it is potently inhibited by proton pump inhibitors, providing a mechanism for PPI-associated fracture risk and for metabolic benefit [PMID:34213594, PMID:38572109].","teleology":[{"year":2003,"claim":"Establishing the structural basis of PHOSPHO1 catalysis was needed to define its enzyme family and substrate specificity; homology modelling placed it in a novel HAD subgroup with a Mg2+-coordinating aspartate triad.","evidence":"Homology modelling on phosphoserine phosphatase crystal structure","pmids":["14983068"],"confidence":"Medium","gaps":["No experimental crystal structure","Predicted specificity residues required mutagenesis to confirm"]},{"year":2004,"claim":"The enzymatic identity of PHOSPHO1 was unknown; in vitro assays defined it as a high-affinity Mg2+-dependent phosphatase toward phosphoethanolamine and phosphocholine producing inorganic phosphate.","evidence":"In vitro enzymatic assay with recombinant human PHOSPHO1 and kinetic parameters","pmids":["15175005"],"confidence":"High","gaps":["Physiological substrate in vivo not yet established","Cellular site of activity not addressed"]},{"year":2004,"claim":"Whether PHOSPHO1 was relevant to mineralization required tissue context; IHC showed exclusive localization to mineralizing skeletal regions and expression only in mineralizing osteoblast lines.","evidence":"Immunohistochemistry of avian skeletal tissue and RT-PCR in osteoblast lines","pmids":["15050893"],"confidence":"Medium","gaps":["Subcellular compartment not resolved","Causal role in mineralization not yet tested"]},{"year":2005,"claim":"The predicted catalytic residues needed validation; mutagenesis confirmed Asp32/Asp203 as essential and showed the paralog PHOSPHO2 has distinct substrate specificity, cementing PHOSPHO1's HAD membership.","evidence":"Site-directed mutagenesis and kinetic assays of recombinant PHOSPHO1 and PHOSPHO2","pmids":["16054448"],"confidence":"High","gaps":["No structural confirmation of the catalytic mechanism","Does not address in vivo substrate"]},{"year":2006,"claim":"Linking PHOSPHO1 to the mineralization machinery required showing where it acts; immunoblotting localized active PHOSPHO1 to matrix vesicles, upregulated with TNAP during chondrocyte differentiation and preceding mineral deposition.","evidence":"Immunoblotting of isolated matrix vesicles, in situ hybridization, qPCR","pmids":["16837257"],"confidence":"High","gaps":["Functional requirement within MVs not yet demonstrated"]},{"year":2007,"claim":"Whether PHOSPHO1 activity is functionally required for MV-mediated calcification was open; activity was confined to sonicated MVs and pharmacological inhibition substantially reduced MV mineralization.","evidence":"HTS-derived inhibitors and mineralization assays on isolated Akp2-/- osteoblast MVs","pmids":["17227223"],"confidence":"High","gaps":["Inhibitor specificity not exhaustively controlled","Genetic confirmation pending"]},{"year":2010,"claim":"Genetic proof and pathway relationship to TNAP were needed; Phospho1 knockout produced skeletal disease, and epistasis with TNAP established cooperative, non-redundant, PPi-independent roles.","evidence":"Knockout and double-knockout mice, histology, MV mineralization, plasma biochemistry","pmids":["20684022","19874193"],"confidence":"High","gaps":["Molecular mediator of the Phospho1-/- bone defect not yet identified at this stage"]},{"year":2010,"claim":"Whether PHOSPHO1's role generalized beyond cell culture required developmental and signalling context; inhibition blocked endochondral mineralization in chick limbs and a hedgehog-defective mutant lacked Phospho1/Tnap expression.","evidence":"Micromass and in ovo inhibition, in situ hybridization, talpid3 mutant analysis","pmids":["20053388"],"confidence":"Medium","gaps":["Direct molecular link between hedgehog signalling and Phospho1 transcription not defined"]},{"year":2014,"claim":"The mechanism driving the Phospho1-/- skeletal phenotype was unresolved; double knockout of Spp1 rescued the defects, establishing accumulated phosphorylated osteopontin as the mediator, mechanistically distinct from the PPi pathway of TNAP deficiency.","evidence":"Phospho1/Spp1 double-knockout mice with LC-MS/MS p-OPN quantification and histology","pmids":["24825455"],"confidence":"High","gaps":["How PHOSPHO1 loss leads to p-OPN accumulation mechanistically not fully resolved"]},{"year":2016,"claim":"The scope of PHOSPHO1 in mineralized tissues and its contribution to MV biogenesis was extended; genetic and phosphate-transporter epistasis showed it acts in MV formation, cementum, and alveolar bone, and PTH suppresses it via cAMP/PKA.","evidence":"Conditional double knockouts with Pit1, AFM of MVs, dental phenotyping, and pharmacological PKA epistasis in osteoblast cultures","pmids":["26773408","27016531","27444010"],"confidence":"Medium","gaps":["Mechanism of MV biogenesis defect unknown","Direct transcriptional targets of PKA on Phospho1 not mapped"]},{"year":2013,"claim":"Whether PHOSPHO1 contributes to pathological calcification was open; knockout and inhibition of vascular smooth muscle cells showed it is critical for vascular mineralization, cooperating with TNAP.","evidence":"Phospho1-/- VSMC cultures with pharmacological inhibitors and mineralization assays","pmids":["22887744"],"confidence":"High","gaps":["In vivo vascular calcification contribution not addressed in this study"]},{"year":2020,"claim":"A role outside the skeleton was unknown; knockout mice were cold-tolerant and protected from obesity/insulin resistance, and phosphocholine accumulation or dietary choline rescue established PHOSPHO1 as a choline-mediated negative regulator of BAT thermogenesis and metabolism.","evidence":"Phospho1-/- mice, cold/HFD challenge, exogenous phosphocholine and dietary choline rescue","pmids":["32554489","33092598"],"confidence":"Medium","gaps":["Tissue source of metabolically relevant PHOSPHO1 activity not isolated","Downstream choline signalling pathway incompletely defined"]},{"year":2021,"claim":"The pharmacology connecting PHOSPHO1 to clinical drug effects was unclear; proton pump inhibitors directly inhibit PHOSPHO1 with sub-micromolar to micromolar IC50s and suppress osteoblast mineralization, offering a mechanism for PPI-associated fracture risk and metabolic benefit.","evidence":"In vitro IC50 determination, osteoblast mineralization assays, and PHOSPHO1-dependent metabolic rescue in HFD mice","pmids":["34213594","38572109"],"confidence":"Medium","gaps":["Off-target contributions of PPIs not fully excluded","In vivo bone-versus-metabolism selectivity unclear"]},{"year":2025,"claim":"Whether PHOSPHO1 has lipid-signalling functions was unexplored; it was shown to possess D609-sensitive PC-PLC and PE-PLC activity generating diacylglycerol and to co-localize with DGKδ, positioning it in a diacylglycerol-generating pathway.","evidence":"In vitro PLC assays, HEK293 overexpression lipidomics, co-sedimentation and co-localization with DGKδ","pmids":["39992810"],"confidence":"Medium","gaps":["Physiological significance of PLC activity not established in vivo","Single lab, first report of this activity","DGKδ interaction not validated reciprocally"]},{"year":null,"claim":"How a single matrix-vesicle phosphatase mechanistically integrates skeletal mineralization, systemic choline/metabolic regulation, and lipid-signalling roles within distinct cellular compartments remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experimental structure of human PHOSPHO1","Mechanism linking PHOSPHO1 loss to phosphorylated osteopontin accumulation unresolved","Compartment-specific contributions to mineralization versus metabolism not separated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,5]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[21]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[4,5,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[21]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,17,18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,8]}],"complexes":[],"partners":["ALPL","DGKD"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8TCT1","full_name":"Phosphoethanolamine/phosphocholine phosphatase","aliases":[],"length_aa":267,"mass_kda":29.7,"function":"Phosphatase that has a high activity toward phosphoethanolamine (PEA) and phosphocholine (PCho) (PubMed:15175005). Involved in the generation of inorganic phosphate for bone mineralization (By similarity). Acts in a non-redundant manner with PHOSPHO1 in skeletal mineralization: while PHOSPHO1 mediates the initiation of hydroxyapatite crystallization in the matrix vesicles (MVs), ALPL/TNAP catalyzes the spread of hydroxyapatite crystallization in the extracellular matrix (By similarity)","subcellular_location":"Extracellular vesicle","url":"https://www.uniprot.org/uniprotkb/Q8TCT1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PHOSPHO1","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PHOSPHO1","total_profiled":1310},"omim":[],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Actin filaments","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"testis","ntpm":90.6}],"url":"https://www.proteinatlas.org/search/PHOSPHO1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q8TCT1","domains":[{"cath_id":"3.40.50.1000","chopping":"28-267","consensus_level":"high","plddt":95.7896,"start":28,"end":267}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TCT1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TCT1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TCT1-F1-predicted_aligned_error_v6.png","plddt_mean":91.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PHOSPHO1","jax_strain_url":"https://www.jax.org/strain/search?query=PHOSPHO1"},"sequence":{"accession":"Q8TCT1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TCT1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TCT1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TCT1"}},"corpus_meta":[{"pmid":"20684022","id":"PMC_20684022","title":"Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification.","date":"2010","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/20684022","citation_count":179,"is_preprint":false},{"pmid":"27148772","id":"PMC_27148772","title":"DNA methylation of loci within ABCG1 and PHOSPHO1 in blood DNA is associated with future type 2 diabetes risk.","date":"2016","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/27148772","citation_count":152,"is_preprint":false},{"pmid":"17227223","id":"PMC_17227223","title":"Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization.","date":"2007","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/17227223","citation_count":143,"is_preprint":false},{"pmid":"15175005","id":"PMC_15175005","title":"Human PHOSPHO1 exhibits high specific phosphoethanolamine and phosphocholine phosphatase activities.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15175005","citation_count":112,"is_preprint":false},{"pmid":"19874193","id":"PMC_19874193","title":"Kinetic analysis of substrate utilization by native and TNAP-, NPP1-, or PHOSPHO1-deficient matrix vesicles.","date":"2010","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19874193","citation_count":111,"is_preprint":false},{"pmid":"15050893","id":"PMC_15050893","title":"PHOSPHO1-A novel phosphatase specifically expressed at sites of mineralisation in bone and cartilage.","date":"2004","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/15050893","citation_count":81,"is_preprint":false},{"pmid":"16837257","id":"PMC_16837257","title":"The presence of PHOSPHO1 in matrix vesicles and its developmental expression prior to skeletal mineralization.","date":"2006","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/16837257","citation_count":69,"is_preprint":false},{"pmid":"20053388","id":"PMC_20053388","title":"Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick.","date":"2010","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/20053388","citation_count":55,"is_preprint":false},{"pmid":"31372594","id":"PMC_31372594","title":"How To Build a Bone: PHOSPHO1, Biomineralization, and Beyond.","date":"2019","source":"JBMR plus","url":"https://pubmed.ncbi.nlm.nih.gov/31372594","citation_count":53,"is_preprint":false},{"pmid":"22887744","id":"PMC_22887744","title":"Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification.","date":"2013","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/22887744","citation_count":51,"is_preprint":false},{"pmid":"26773408","id":"PMC_26773408","title":"Skeletal Mineralization Deficits and Impaired Biogenesis and Function of Chondrocyte-Derived Matrix Vesicles in Phospho1(-/-) and Phospho1/Pi t1 Double-Knockout Mice.","date":"2016","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/26773408","citation_count":48,"is_preprint":false},{"pmid":"24825455","id":"PMC_24825455","title":"Ablation of osteopontin improves the skeletal phenotype of phospho1(-/-) mice.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24825455","citation_count":47,"is_preprint":false},{"pmid":"14983068","id":"PMC_14983068","title":"Comparative modelling of human PHOSPHO1 reveals a new group of phosphatases within the haloacid dehalogenase superfamily.","date":"2003","source":"Protein engineering","url":"https://pubmed.ncbi.nlm.nih.gov/14983068","citation_count":40,"is_preprint":false},{"pmid":"16054448","id":"PMC_16054448","title":"Probing the substrate specificities of human PHOSPHO1 and PHOSPHO2.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16054448","citation_count":32,"is_preprint":false},{"pmid":"26457330","id":"PMC_26457330","title":"The Functional co-operativity of Tissue-Nonspecific Alkaline Phosphatase (TNAP) and PHOSPHO1 during initiation of Skeletal Mineralization.","date":"2015","source":"Biochemistry and biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/26457330","citation_count":28,"is_preprint":false},{"pmid":"32554489","id":"PMC_32554489","title":"Phosphocholine accumulation and PHOSPHO1 depletion promote adipose tissue thermogenesis.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32554489","citation_count":21,"is_preprint":false},{"pmid":"27016531","id":"PMC_27016531","title":"Role of PHOSPHO1 in Periodontal Development and Function.","date":"2016","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/27016531","citation_count":19,"is_preprint":false},{"pmid":"28737011","id":"PMC_28737011","title":"A distinctive patchy osteomalacia characterises Phospho1-deficient mice.","date":"2017","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/28737011","citation_count":18,"is_preprint":false},{"pmid":"33092598","id":"PMC_33092598","title":"PHOSPHO1 is a skeletal regulator of insulin resistance and obesity.","date":"2020","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/33092598","citation_count":17,"is_preprint":false},{"pmid":"35900032","id":"PMC_35900032","title":"Increased PHOSPHO1 expression mediates cortical bone mineral density in renal osteodystrophy.","date":"2022","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35900032","citation_count":16,"is_preprint":false},{"pmid":"12464021","id":"PMC_12464021","title":"Chromosomal localization of the chicken and mammalian orthologues of the orphan phosphatase PHOSPHO1 gene.","date":"2002","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12464021","citation_count":15,"is_preprint":false},{"pmid":"34213594","id":"PMC_34213594","title":"Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro.","date":"2021","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/34213594","citation_count":14,"is_preprint":false},{"pmid":"27444010","id":"PMC_27444010","title":"The Expression of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in Mineralising Osteoblast Cultures.","date":"2016","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/27444010","citation_count":12,"is_preprint":false},{"pmid":"29089903","id":"PMC_29089903","title":"Intravesicular Phosphatase PHOSPHO1 Function in Enamel Mineralization and Prism Formation.","date":"2017","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29089903","citation_count":12,"is_preprint":false},{"pmid":"36185572","id":"PMC_36185572","title":"Perspective on Dentoalveolar Manifestations Resulting From PHOSPHO1 Loss-of-Function: A Form of Pseudohypophosphatasia?","date":"2022","source":"Frontiers in dental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36185572","citation_count":8,"is_preprint":false},{"pmid":"38572109","id":"PMC_38572109","title":"Repurposing lansoprazole to alleviate metabolic syndrome via PHOSPHO1 inhibition.","date":"2024","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/38572109","citation_count":7,"is_preprint":false},{"pmid":"18471996","id":"PMC_18471996","title":"Identification of a novel splice variant of the haloacid dehalogenase: PHOSPHO1.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18471996","citation_count":6,"is_preprint":false},{"pmid":"39992810","id":"PMC_39992810","title":"Human PHOSPHO1 exhibits phosphatidylcholine- and phosphatidylethanolamine-phospholipase C activities and interacts with diacylglycerol kinase δ.","date":"2025","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/39992810","citation_count":5,"is_preprint":false},{"pmid":"40470038","id":"PMC_40470038","title":"Distinct bone metabolic networks identified in Phospho1-/- mice vs. wild type mice using [18F]FDG total-body PET.","date":"2025","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40470038","citation_count":4,"is_preprint":false},{"pmid":"36540015","id":"PMC_36540015","title":"Increased PHOSPHO1 and alkaline phosphatase expression during the anabolic bone response to intermittent parathyroid hormone delivery.","date":"2022","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/36540015","citation_count":3,"is_preprint":false},{"pmid":"35943680","id":"PMC_35943680","title":"PHOSPHO1 Serves as a Key Metabolism-Related Biomarker in the Tumorigenesis of Diffuse Large B-cell Lymphoma.","date":"2022","source":"Current medical science","url":"https://pubmed.ncbi.nlm.nih.gov/35943680","citation_count":3,"is_preprint":false},{"pmid":"23860651","id":"PMC_23860651","title":"The use of tissue-nonspecific alkaline phosphatase (TNAP) and PHOSPHO1 inhibitors to affect mineralization by cultured cells.","date":"2013","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/23860651","citation_count":2,"is_preprint":false},{"pmid":"32693758","id":"PMC_32693758","title":"PHOSPHO1 Gene DNA Methylations are Associated with a Change in HDL-C Response to Simvastatin Treatment.","date":"2020","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/32693758","citation_count":1,"is_preprint":false},{"pmid":"40574346","id":"PMC_40574346","title":"Co-overexpression of the caloric restriction-induced mitochondrial factors PGC-1α and MIPEP upregulates Phospho1 expression in adipocytes.","date":"2025","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/40574346","citation_count":1,"is_preprint":false},{"pmid":"41664674","id":"PMC_41664674","title":"Methylation analysis of PHOSPHO1 and ACACA gene promoters in whole blood samples: insights into metabolic syndrome and associated factors.","date":"2026","source":"Journal of diabetes and metabolic disorders","url":"https://pubmed.ncbi.nlm.nih.gov/41664674","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":20655,"output_tokens":6166,"usd":0.077228,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15292,"output_tokens":4543,"usd":0.095018,"stage2_stop_reason":"end_turn"},"total_usd":0.172246,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"Human PHOSPHO1 exhibits high specific phosphatase activities toward phosphoethanolamine (PEA) and phosphocholine (PCho), generating inorganic phosphate (Pi). Optimal activity is at pH ~6.7, requires Mg2+, with Km values of 3.0 µM for PEA and 11.4 µM for PCho.\",\n      \"method\": \"In vitro enzymatic assay with recombinant human PHOSPHO1\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro enzymatic characterization with kinetic parameters, replicated in subsequent studies\",\n      \"pmids\": [\"15175005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Comparative modelling of human PHOSPHO1 based on phosphoserine phosphatase crystal structure revealed a catalytic Mg2+ coordinated by conserved Asp32, Asp34, and Asp203; Asp43 and Asp123 (not present in PSPs) contribute to substrate specificity, placing PHOSPHO1 in a novel subgroup of the HAD superfamily distinct from phosphoserine phosphatases.\",\n      \"method\": \"Homology modelling based on crystal structure of phosphoserine phosphatase from Methanococcus jannaschii\",\n      \"journal\": \"Protein engineering\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 (structural model) / Weak — single-lab computational model without experimental structural validation; functional predictions later partially confirmed by mutagenesis\",\n      \"pmids\": [\"14983068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Active-site mutagenesis of PHOSPHO1 confirmed that Asp32 and Asp203 are essential catalytic residues; mutation of either abolishes activity, confirming membership in the HAD superfamily. Asp43 and Asp123 are also important for substrate hydrolysis. By contrast, PHOSPHO2 (42% identity) shows high activity toward pyridoxal-5-phosphate rather than PEA/PCho, indicating distinct substrate specificities despite similar active-site architecture.\",\n      \"method\": \"Site-directed mutagenesis of recombinant PHOSPHO1 and PHOSPHO2, in vitro enzymatic assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — active-site mutagenesis combined with kinetic characterization of both paralogs in a single study\",\n      \"pmids\": [\"16054448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PHOSPHO1 protein localizes exclusively to mineralizing regions: osteoid of periosteum, forming surfaces of growing osteons, newly formed osteocytes, early hypertrophic chondrocytes of growth plate, and primary spongiosa; absent from soft tissues. PHOSPHO1 gene expression is detected in mineralizing SaOS-2 but not non-mineralizing MG-63 osteoblast-like cells.\",\n      \"method\": \"Immunohistochemistry of avian skeletal tissues with affinity-purified antiserum; RT-PCR in osteoblast cell lines\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by IHC with functional correlation (mineralizing vs. non-mineralizing cells), replicated across subsequent studies\",\n      \"pmids\": [\"15050893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PHOSPHO1 is present within matrix vesicles (MVs) isolated from growth plate chondrocytes, as confirmed by immunoblotting. PHOSPHO1 expression in MVs is upregulated alongside TNAP activity when chondrocytes are induced to differentiate with ascorbic acid. PHOSPHO1 mRNA expression during chick embryogenesis precedes mineral deposition, appearing first in the bone collar of the diaphysis.\",\n      \"method\": \"Immunoblotting of isolated MVs; whole-mount in situ hybridization; qPCR; alizarin red/alcian blue staining\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct MV localization by Western blot replicated by multiple subsequent studies; developmental expression precedes mineralization confirmed independently\",\n      \"pmids\": [\"16837257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PHOSPHO1 is functionally present within MVs in an active state (PEA hydrolase activity detected in sonicated but not intact MVs from TNAP-deficient osteoblasts). Pharmacological inhibition of PHOSPHO1 with lansoprazole or SCH202676 reduced MV-mediated mineralization by 56.8% and 70.7%, respectively, establishing a functional role in the initiation of MV-mediated calcification.\",\n      \"method\": \"High-throughput screening of chemical libraries; enzymatic assay on sonicated/intact MVs from Akp2-/- osteoblasts; mineralization assay with isolated MVs\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — enzymatic activity in isolated MVs combined with pharmacological inhibition and mineralization readout; replicated across labs\",\n      \"pmids\": [\"17227223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Genetic ablation of PHOSPHO1 (Phospho1-/- mice) causes growth plate abnormalities, spontaneous fractures, bowed long bones, osteomalacia, and scoliosis. Primary Phospho1-/- chondrocytes and their MVs show reduced mineralizing ability. Plasma PP(i) is elevated in Phospho1-/- mice. Transgenic overexpression of TNAP in Phospho1-/- mice normalizes PP(i) but does NOT correct the bone phenotype, demonstrating PHOSPHO1 has a non-redundant role independent of PP(i) control. Double ablation of PHOSPHO1 and TNAP completely abolishes skeletal mineralization and causes perinatal lethality, establishing their cooperative, non-redundant roles.\",\n      \"method\": \"Knockout mouse generation; histology; primary chondrocyte culture; MV isolation and mineralization assay; biochemical plasma analysis; genetic double-knockout epistasis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with multiple knockout models, multiple orthogonal phenotypic readouts, replicated across labs\",\n      \"pmids\": [\"20684022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PHOSPHO1 deficiency in MVs secondarily reduces TNAP levels in Phospho1-/- MVs, affecting ATP hydrolysis in those MVs. TNAP is the primary enzyme hydrolyzing both ATP and PP(i) within the MV compartment; lack of NPP1 does not significantly affect MV kinetic parameters for any substrate.\",\n      \"method\": \"Kinetic analysis of phosphosubstrate hydrolysis by isolated MVs from WT, TNAP-/-, NPP1-/-, and PHOSPHO1-/- osteoblasts at physiologic pH\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct kinetic comparison across four genetically defined MV preparations, rigorous biochemical assay\",\n      \"pmids\": [\"19874193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Pharmacological inhibition of PHOSPHO1 (lansoprazole) in developing chick limb micromass cultures and in ovo completely inhibited mineralization of long bones. PHOSPHO1 and TNAP are co-expressed in a tightly regulated pattern preceding mineralization. The talpid3 chick mutant (defective hedgehog signaling, no endochondral mineralization) lacks Phospho1 and Tnap expression, while flat bones that mineralize normally express both, linking hedgehog signaling to PHOSPHO1-dependent endochondral ossification.\",\n      \"method\": \"In vitro micromass cultures with lansoprazole inhibitor; whole-mount RNA in situ hybridization; talpid3 mutant analysis; alizarin red/alcian blue staining\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition in two experimental systems plus genetic mutant comparison, single lab\",\n      \"pmids\": [\"20053388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PHOSPHO1 is expressed in vascular smooth muscle cells (VSMCs) under calcifying conditions, and Phospho1-/- VSMCs fail to mineralize in vitro. Pharmacological inhibition of PHOSPHO1 with MLS-0263839 reduced VSMC calcification to 41.8% of control; combined PHOSPHO1 + TNAP inhibition reduced it to 20.9% of control, demonstrating PHOSPHO1 plays a critical role in VSMC (vascular) mineralization.\",\n      \"method\": \"Knockout VSMC cultures; pharmacological inhibitors; mineralization assay; gene expression analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout combined with pharmacological inhibition and quantitative mineralization readout, multiple orthogonal approaches\",\n      \"pmids\": [\"22887744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Phospho1-/- mice have elevated plasma osteopontin (OPN) and increased proportion of phosphorylated OPN (p-OPN) in the skeleton detected by LC-MS/MS. Ablation of Spp1 (OPN gene) in Phospho1-/- mice rescues scoliosis and improves long bone defects and normalizes chondrocyte differentiation markers, establishing that accumulated phosphorylated OPN mediates the skeletal abnormalities in Phospho1-/- mice (distinct from the PP(i)-mediated mechanism in TNAP-deficient mice).\",\n      \"method\": \"Double-knockout mouse generation; LC-MS/MS for p-OPN quantification; histology; mineralization assay; gene expression analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (double KO) with LC-MS/MS biochemical validation and multiple phenotypic readouts\",\n      \"pmids\": [\"24825455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Combined genetic ablation of Phospho1 and the phosphate transporter Pit1 (Slc20a1, col2a1-Cre) produces more severe skeletal deformities than Phospho1-/- alone. ~80% of [Phospho1-/-; Pit1col2/col2] MVs are devoid of mineral vs. ~50% for Phospho1-/- and ~25% for WT, assessed by atomic force microscopy. PHOSPHO1 function is also involved in MV biogenesis, as both Phospho1-/- and double-KO chondrocytes produce significantly fewer MVs.\",\n      \"method\": \"Conditional double-knockout mouse model; atomic force microscopy of MVs; histology; micro-CT; biomechanical testing\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double conditional KO, quantitative AFM of MV mineral content, multiple orthogonal structural and functional readouts\",\n      \"pmids\": [\"26773408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PTH continuously downregulates Phospho1 and Smpd3 (nSMase2) gene expression in osteoblast cultures and hemi-calvariae. This effect is mimicked by the cAMP agonist forskolin and blocked by the PKA inhibitor PKI(5-24), identifying the cAMP/PKA pathway as the mediator of PTH-driven PHOSPHO1 suppression. BMP-2's stimulatory effect on Phospho1 expression is abolished by PTH.\",\n      \"method\": \"In vitro osteoblast cultures (MC3T3-C14); hemi-calvaria cultures; pharmacological agonist/inhibitor studies; gene expression analysis (qPCR)\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway placement via pharmacological epistasis (cAMP agonist + PKA inhibitor), two model systems, single lab\",\n      \"pmids\": [\"27444010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PHOSPHO1 (expressed by cementoblasts and alveolar bone osteoblasts) is required for cellular cementum and alveolar bone mineralization. Phospho1-/- mice show increased cementoid (delayed mineralization) in cellular cementum and unmineralized osteoid in alveolar bone with elevated OPN deposition, while acellular cementum is unaffected, demonstrating acellular cementum does not rely on MV-mediated (PHOSPHO1-dependent) initiation of mineralization.\",\n      \"method\": \"Phospho1-/- mouse analysis; histology; immunohistochemistry; in situ hybridization; micro-CT; radiography\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout mouse with tissue-specific phenotypic readouts and spatial protein localization, single lab\",\n      \"pmids\": [\"27016531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PHOSPHO1 and TNAP have non-redundant, cooperative roles in osteoblast mineralization. In MC3T3-E1 clone 24 cells (low PHOSPHO1/high TNAP), lentiviral PHOSPHO1 overexpression increases both PHOSPHO1 and TNAP protein and enhances mineralization. Simultaneous pharmacological inhibition of both PHOSPHO1 and TNAP essentially abolishes mineralization (85% reduction), whereas individual inhibitors only partially suppress it.\",\n      \"method\": \"Lentiviral overexpression; pharmacological inhibitors (MLS-0263839 and MLS-0038949); mineralization assays in MC3T3-E1 cell clones and ex vivo metatarsal cultures\",\n      \"journal\": \"Biochemistry and biophysics reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal gain/loss-of-function approaches in multiple model systems, single lab\",\n      \"pmids\": [\"26457330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A novel alternatively spliced PHOSPHO1 transcript (PHOSPHO1-3a) was identified, encoding a 292-amino-acid protein with a 40-amino-acid N-terminal region containing a predicted secretory signal while retaining all three HAD superfamily catalytic domains. Expression confirmed in human and mouse osteoblast-like cells and chondrogenic ATDC5 cells.\",\n      \"method\": \"RT-PCR; sequence analysis; expression in osteoblast and chondrogenic cell lines\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — transcript identification confirmed by RT-PCR in multiple cell lines but no functional characterization of the protein isoform\",\n      \"pmids\": [\"18471996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PHOSPHO1 localizes to ameloblast Tomes' processes and secretory vesicle walls (co-localizing with amelogenin and the exosomal marker HSP70). Phospho1-/- mice display reduced enamel mineralization (2-fold reduction in von Kossa silver grain density), loss of enamel prism 'picket fence' structure, loss of parallel crystal organization, increased prism width, and decreased phosphate incorporation by EDS, establishing PHOSPHO1 as essential for enamel mineralization.\",\n      \"method\": \"Immunohistochemistry; Western blot; scanning electron microscopy; EDS elemental analysis; von Kossa staining; Phospho1-/- mouse model\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout mouse with multiple structural and quantitative mineral readouts, single lab\",\n      \"pmids\": [\"29089903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PHOSPHO1 knockout mice are cold-tolerant and protected from high-fat diet-induced obesity and insulin resistance. PHOSPHO1 substrate phosphocholine (PC) accumulation (via exogenous PC treatment) is sufficient to induce thermogenic gene expression in BAT and cold tolerance, establishing PHOSPHO1 as a negative regulator of BAT thermogenesis through its phosphocholine phosphatase activity.\",\n      \"method\": \"Phospho1-/- mouse model; cold tolerance testing; high-fat diet challenge; thermogenic gene expression analysis; exogenous phosphocholine treatment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO combined with substrate rescue experiment, two orthogonal approaches, single lab\",\n      \"pmids\": [\"32554489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Phospho1-/- mice exhibit improved basal glucose homeostasis and resist high-fat diet-induced weight gain and diabetes independently of osteocalcin levels. Decreased serum choline in Phospho1-/- mice is normalized by 2% choline diet feeding, which also normalizes insulin sensitivity and fat mass, establishing that PHOSPHO1's metabolic regulation is mediated via choline availability.\",\n      \"method\": \"Phospho1-/- mouse model; HFD challenge; dietary choline supplementation rescue; serum metabolite measurement; gene expression analysis in osteoblasts\",\n      \"journal\": \"BMC biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with dietary rescue experiment establishing the choline-mediated mechanism, single lab\",\n      \"pmids\": [\"33092598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"All tested proton pump inhibitors (PPIs) inhibit PHOSPHO1 enzymatic activity in vitro (IC50 range: 0.73 µM for esomeprazole to 19.27 µM for pantoprazole), whereas histamine-2 receptor antagonists do not. Several PPIs inhibit mineralization of bone matrix in primary osteoblast cultures in a concentration-dependent manner, providing a potential mechanism for PPI-associated fracture risk.\",\n      \"method\": \"In vitro PHOSPHO1 enzymatic inhibition assay; primary osteoblast mineralization cultures\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct enzymatic IC50 determination combined with cell-based mineralization assay, single lab\",\n      \"pmids\": [\"34213594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In a CKD (renal osteodystrophy) mouse model, cortical bone mineral density is increased alongside upregulated PHOSPHO1 expression. In Phospho1-/- CKD mice, the cortical BMD increase is rescued, establishing that elevated PHOSPHO1 expression directly drives the cortical BMD phenotype in CKD. PTH and phosphate treatment of primary osteoblasts downregulate both PHOSPHO1 and TNAP expression.\",\n      \"method\": \"Dietary adenine CKD model in WT and Phospho1-/- mice; micro-CT; primary osteoblast cultures with PTH/phosphate treatment; gene expression analysis\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue in KO CKD model with quantitative BMD readout and in vitro mechanistic follow-up, single lab\",\n      \"pmids\": [\"35900032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PHOSPHO1 (cytosolic protein) exhibits D609-sensitive phosphatidylcholine-PLC (PC-PLC) and phosphatidylethanolamine-PLC (PE-PLC) activities in vitro, generating diacylglycerol (DG). Overexpression of PHOSPHO1 in HEK293 cells significantly increases cellular levels of saturated/monounsaturated fatty acid-containing DG. PHOSPHO1 co-sediments and co-localizes with diacylglycerol kinase δ (DGKδ), identifying it as a candidate cytosolic PC-/PE-PLC acting upstream of DGKδ.\",\n      \"method\": \"In vitro PLC activity assay; PHOSPHO1 overexpression in HEK293 cells; lipidomic analysis; co-sedimentation; co-localization\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Weak — novel activity demonstrated in vitro with cellular overexpression and co-sedimentation, but single lab, first report of this activity\",\n      \"pmids\": [\"39992810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Lansoprazole (LPZ) inhibits adipose PHOSPHO1 (phosphocholine phosphatase) activity and produces metabolic benefits (reduced obesity, insulin resistance, hepatic steatosis, induction of thermogenic gene expression) in a PHOSPHO1-dependent manner in mice. Mechanistically, LPZ may stimulate thermogenesis by inhibiting conversion of 2-AG-LPA to 2-AG, reducing cannabinoid receptor signaling.\",\n      \"method\": \"In vitro PHOSPHO1 inhibition assay; HFD mouse model with LPZ treatment; PHOSPHO1-dependent rescue experiments; gene expression analysis; mitochondrial respiration assay\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition validated in PHOSPHO1-dependent manner with in vitro and in vivo readouts, single lab\",\n      \"pmids\": [\"38572109\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PHOSPHO1 is a Mg2+-dependent phosphatase of the HAD superfamily (catalytic residues Asp32, Asp203, Asp43, Asp123) that hydrolyzes phosphoethanolamine and phosphocholine to generate inorganic phosphate within matrix vesicles, initiating hydroxyapatite crystal nucleation during endochondral ossification; it also exhibits PC-PLC and PE-PLC activities generating diacylglycerol and acts as a negative regulator of brown adipose tissue thermogenesis through phosphocholine hydrolysis, with its catabolic effects on choline availability mediating systemic metabolic regulation, while its expression is controlled by the cAMP/PKA pathway downstream of PTH signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PHOSPHO1 is a Mg2+-dependent phosphatase of the HAD superfamily that initiates skeletal mineralization by hydrolyzing phosphoethanolamine and phosphocholine within matrix vesicles to generate the inorganic phosphate required for hydroxyapatite crystal nucleation [#0, #4, #5]. Catalysis depends on the conserved active-site aspartates Asp32 and Asp203, with Asp43 and Asp123 conferring substrate specificity that distinguishes it from phosphoserine phosphatases and from the paralog PHOSPHO2 [#1, #2]. The protein is restricted to mineralizing tissues and packaged into matrix vesicles of growth plate chondrocytes and osteoblasts, where its expression precedes mineral deposition [#3, #4]. Genetic ablation produces growth plate abnormalities, spontaneous fractures, bowed long bones, and osteomalacia, and PHOSPHO1 cooperates non-redundantly with the alkaline phosphatase TNAP: double ablation abolishes skeletal mineralization and causes perinatal lethality, while TNAP overexpression cannot rescue the Phospho1-/- bone defect despite normalizing pyrophosphate [#6, #14]. The Phospho1-/- skeletal phenotype is instead mediated by accumulation of phosphorylated osteopontin, since co-deletion of Spp1 rescues the abnormalities [#10]. PHOSPHO1-dependent matrix-vesicle mineralization also drives cementum, alveolar bone, enamel, and pathological vascular smooth muscle cell calcification [#9, #13, #16]. Beyond mineralization, PHOSPHO1 acts as a negative regulator of brown adipose tissue thermogenesis and systemic glucose homeostasis through its phosphocholine phosphatase activity, with effects mediated by choline availability [#17, #18]. It additionally exhibits PC-PLC and PE-PLC activity generating diacylglycerol and co-localizes with diacylglycerol kinase \\u03b4 [#21]. Its expression is suppressed by PTH via the cAMP/PKA pathway [#12], and it is potently inhibited by proton pump inhibitors, providing a mechanism for PPI-associated fracture risk and for metabolic benefit [#19, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Establishing the structural basis of PHOSPHO1 catalysis was needed to define its enzyme family and substrate specificity; homology modelling placed it in a novel HAD subgroup with a Mg2+-coordinating aspartate triad.\",\n      \"evidence\": \"Homology modelling on phosphoserine phosphatase crystal structure\",\n      \"pmids\": [\"14983068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimental crystal structure\", \"Predicted specificity residues required mutagenesis to confirm\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The enzymatic identity of PHOSPHO1 was unknown; in vitro assays defined it as a high-affinity Mg2+-dependent phosphatase toward phosphoethanolamine and phosphocholine producing inorganic phosphate.\",\n      \"evidence\": \"In vitro enzymatic assay with recombinant human PHOSPHO1 and kinetic parameters\",\n      \"pmids\": [\"15175005\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrate in vivo not yet established\", \"Cellular site of activity not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Whether PHOSPHO1 was relevant to mineralization required tissue context; IHC showed exclusive localization to mineralizing skeletal regions and expression only in mineralizing osteoblast lines.\",\n      \"evidence\": \"Immunohistochemistry of avian skeletal tissue and RT-PCR in osteoblast lines\",\n      \"pmids\": [\"15050893\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Subcellular compartment not resolved\", \"Causal role in mineralization not yet tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The predicted catalytic residues needed validation; mutagenesis confirmed Asp32/Asp203 as essential and showed the paralog PHOSPHO2 has distinct substrate specificity, cementing PHOSPHO1's HAD membership.\",\n      \"evidence\": \"Site-directed mutagenesis and kinetic assays of recombinant PHOSPHO1 and PHOSPHO2\",\n      \"pmids\": [\"16054448\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural confirmation of the catalytic mechanism\", \"Does not address in vivo substrate\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linking PHOSPHO1 to the mineralization machinery required showing where it acts; immunoblotting localized active PHOSPHO1 to matrix vesicles, upregulated with TNAP during chondrocyte differentiation and preceding mineral deposition.\",\n      \"evidence\": \"Immunoblotting of isolated matrix vesicles, in situ hybridization, qPCR\",\n      \"pmids\": [\"16837257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional requirement within MVs not yet demonstrated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Whether PHOSPHO1 activity is functionally required for MV-mediated calcification was open; activity was confined to sonicated MVs and pharmacological inhibition substantially reduced MV mineralization.\",\n      \"evidence\": \"HTS-derived inhibitors and mineralization assays on isolated Akp2-/- osteoblast MVs\",\n      \"pmids\": [\"17227223\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitor specificity not exhaustively controlled\", \"Genetic confirmation pending\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Genetic proof and pathway relationship to TNAP were needed; Phospho1 knockout produced skeletal disease, and epistasis with TNAP established cooperative, non-redundant, PPi-independent roles.\",\n      \"evidence\": \"Knockout and double-knockout mice, histology, MV mineralization, plasma biochemistry\",\n      \"pmids\": [\"20684022\", \"19874193\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mediator of the Phospho1-/- bone defect not yet identified at this stage\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Whether PHOSPHO1's role generalized beyond cell culture required developmental and signalling context; inhibition blocked endochondral mineralization in chick limbs and a hedgehog-defective mutant lacked Phospho1/Tnap expression.\",\n      \"evidence\": \"Micromass and in ovo inhibition, in situ hybridization, talpid3 mutant analysis\",\n      \"pmids\": [\"20053388\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between hedgehog signalling and Phospho1 transcription not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The mechanism driving the Phospho1-/- skeletal phenotype was unresolved; double knockout of Spp1 rescued the defects, establishing accumulated phosphorylated osteopontin as the mediator, mechanistically distinct from the PPi pathway of TNAP deficiency.\",\n      \"evidence\": \"Phospho1/Spp1 double-knockout mice with LC-MS/MS p-OPN quantification and histology\",\n      \"pmids\": [\"24825455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PHOSPHO1 loss leads to p-OPN accumulation mechanistically not fully resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The scope of PHOSPHO1 in mineralized tissues and its contribution to MV biogenesis was extended; genetic and phosphate-transporter epistasis showed it acts in MV formation, cementum, and alveolar bone, and PTH suppresses it via cAMP/PKA.\",\n      \"evidence\": \"Conditional double knockouts with Pit1, AFM of MVs, dental phenotyping, and pharmacological PKA epistasis in osteoblast cultures\",\n      \"pmids\": [\"26773408\", \"27016531\", \"27444010\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of MV biogenesis defect unknown\", \"Direct transcriptional targets of PKA on Phospho1 not mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Whether PHOSPHO1 contributes to pathological calcification was open; knockout and inhibition of vascular smooth muscle cells showed it is critical for vascular mineralization, cooperating with TNAP.\",\n      \"evidence\": \"Phospho1-/- VSMC cultures with pharmacological inhibitors and mineralization assays\",\n      \"pmids\": [\"22887744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo vascular calcification contribution not addressed in this study\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A role outside the skeleton was unknown; knockout mice were cold-tolerant and protected from obesity/insulin resistance, and phosphocholine accumulation or dietary choline rescue established PHOSPHO1 as a choline-mediated negative regulator of BAT thermogenesis and metabolism.\",\n      \"evidence\": \"Phospho1-/- mice, cold/HFD challenge, exogenous phosphocholine and dietary choline rescue\",\n      \"pmids\": [\"32554489\", \"33092598\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue source of metabolically relevant PHOSPHO1 activity not isolated\", \"Downstream choline signalling pathway incompletely defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The pharmacology connecting PHOSPHO1 to clinical drug effects was unclear; proton pump inhibitors directly inhibit PHOSPHO1 with sub-micromolar to micromolar IC50s and suppress osteoblast mineralization, offering a mechanism for PPI-associated fracture risk and metabolic benefit.\",\n      \"evidence\": \"In vitro IC50 determination, osteoblast mineralization assays, and PHOSPHO1-dependent metabolic rescue in HFD mice\",\n      \"pmids\": [\"34213594\", \"38572109\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Off-target contributions of PPIs not fully excluded\", \"In vivo bone-versus-metabolism selectivity unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Whether PHOSPHO1 has lipid-signalling functions was unexplored; it was shown to possess D609-sensitive PC-PLC and PE-PLC activity generating diacylglycerol and to co-localize with DGK\\u03b4, positioning it in a diacylglycerol-generating pathway.\",\n      \"evidence\": \"In vitro PLC assays, HEK293 overexpression lipidomics, co-sedimentation and co-localization with DGK\\u03b4\",\n      \"pmids\": [\"39992810\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological significance of PLC activity not established in vivo\", \"Single lab, first report of this activity\", \"DGK\\u03b4 interaction not validated reciprocally\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single matrix-vesicle phosphatase mechanistically integrates skeletal mineralization, systemic choline/metabolic regulation, and lipid-signalling roles within distinct cellular compartments remains unresolved.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimental structure of human PHOSPHO1\", \"Mechanism linking PHOSPHO1 loss to phosphorylated osteopontin accumulation unresolved\", \"Compartment-specific contributions to mineralization versus metabolism not separated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [4, 5, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 17, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ALPL\",\n      \"DGKD\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}